JP7885124B2 - 長時間作用型ｇｌｐ－１化合物 - Google Patents

長時間作用型ｇｌｐ－１化合物

Info

Publication number
JP7885124B2
JP7885124B2 JP2022540870A JP2022540870A JP7885124B2 JP 7885124 B2 JP7885124 B2 JP 7885124B2 JP 2022540870 A JP2022540870 A JP 2022540870A JP 2022540870 A JP2022540870 A JP 2022540870A JP 7885124 B2 JP7885124 B2 JP 7885124B2
Authority
JP
Japan
Prior art keywords
human insulin
desb30 human
γglu
eicosanedioyl
αglu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022540870A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023510218A5 (cg-RX-API-DMAC10.html
JP2023510218A (ja
Inventor
ガン，ジョォンルー
チェン，ウェイ
ジャン，イイニン
シュエ，ファンカイ
ツァイ，リンギュ
ニィウ，ジァンホン
ム，ビン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gan and Lee Pharmaceuticals Co Ltd
Original Assignee
Gan and Lee Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gan and Lee Pharmaceuticals Co Ltd filed Critical Gan and Lee Pharmaceuticals Co Ltd
Publication of JP2023510218A publication Critical patent/JP2023510218A/ja
Publication of JP2023510218A5 publication Critical patent/JP2023510218A5/ja
Application granted granted Critical
Publication of JP7885124B2 publication Critical patent/JP7885124B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pens And Brushes (AREA)
  • Footwear And Its Accessory, Manufacturing Method And Apparatuses (AREA)
JP2022540870A 2019-12-30 2020-12-29 長時間作用型ｇｌｐ－１化合物 Active JP7885124B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201911397405.2 2019-12-30
CN201911397405 2019-12-30
CN202011053306 2020-09-29
CN202011053306.5 2020-09-29
PCT/CN2020/141057 WO2021136303A1 (zh) 2019-12-30 2020-12-29 长效glp-1化合物

Publications (3)

Publication Number Publication Date
JP2023510218A JP2023510218A (ja) 2023-03-13
JP2023510218A5 JP2023510218A5 (cg-RX-API-DMAC10.html) 2025-10-27
JP7885124B2 true JP7885124B2 (ja) 2026-07-06

Family

ID=76687327

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022540870A Active JP7885124B2 (ja) 2019-12-30 2020-12-29 長時間作用型ｇｌｐ－１化合物

Country Status (10)

Country Link
US (2) US12703731B2 (cg-RX-API-DMAC10.html)
EP (1) EP4086277A4 (cg-RX-API-DMAC10.html)
JP (1) JP7885124B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220119731A (cg-RX-API-DMAC10.html)
CN (5) CN119529057A (cg-RX-API-DMAC10.html)
AU (1) AU2020418207A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022013042A2 (cg-RX-API-DMAC10.html)
CA (1) CA3166496A1 (cg-RX-API-DMAC10.html)
MX (1) MX2022008139A (cg-RX-API-DMAC10.html)
WO (1) WO2021136303A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
CN117561072A (zh) * 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物
CA3231953A1 (en) 2021-09-15 2023-03-23 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
CN118103391A (zh) * 2021-11-12 2024-05-28 福建盛迪医药有限公司 Glp-1受体和gip受体双重激动剂的药物组合物及其用途
WO2023143458A1 (zh) * 2022-01-28 2023-08-03 甘李药业股份有限公司 酰化胰岛素
CN120731085A (zh) * 2023-03-02 2025-09-30 甘李药业股份有限公司 一种glp-1化合物的医药用途
JP2026517987A (ja) * 2023-05-24 2026-06-02 ザ ユナイテッド バイオテクノロジー（ヘンチン）シーオー．，エルティーディー． インスリン誘導体およびその使用
EP4741420A1 (en) * 2023-06-30 2026-05-13 Huonslab Co., Ltd. Pharmaceutical composition for preventing or treating obesity comprising glp analogue as active ingredient
AU2024358560A1 (en) 2023-10-09 2026-05-14 Gan & Lee Pharmaceuticals Co., Ltd. Glp -1 peptide composition and use thereof
IL328182A (en) 2023-11-06 2026-07-01 Gan & Lee Pharmaceuticals Co Ltd GLP-1 receptor agonist for weight loss
WO2025098415A1 (zh) 2023-11-06 2025-05-15 甘李药业股份有限公司 用于降糖的glp-1化合物
WO2025098457A1 (zh) * 2023-11-07 2025-05-15 甘李药业股份有限公司 用于降糖的酰化胰岛素
CN122555570A (zh) * 2023-11-08 2026-08-11 甘李药业股份有限公司 包含胰岛素衍生物的药物组合物的治疗用途
WO2025124473A1 (zh) * 2023-12-12 2025-06-19 江苏恒瑞医药股份有限公司 Glp-1类似物治疗代谢疾病的方法及医药用途
WO2026109062A1 (zh) * 2024-11-25 2026-05-28 甘李药业股份有限公司 含酰化胰岛素的药物组合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ199391A (en) 1981-01-02 1985-12-13 Genentech Inc Chimeric polypeptides comprising a proinsulin sequence,and preparation by recombinant dna technique;production of human insulin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
DK336188D0 (da) 1988-06-20 1988-06-20 Nordisk Gentofte Propeptider
HUT56857A (en) 1988-12-23 1991-10-28 Novo Nordisk As Human insulin analogues
IL93282A (en) 1989-02-09 1995-08-31 Lilly Co Eli Insulin analogues
NZ273285A (en) 1993-09-17 1997-10-24 Novo Nordisk As Insulin derivatives and compositions thereof
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
US6500645B1 (en) 1994-06-17 2002-12-31 Novo Nordisk A/S N-terminally extended proteins expressed in yeast
KR0150565B1 (ko) 1995-02-15 1998-08-17 김정재 유전자 조환에 의한 사람 인슐린 전구체의 제조 및 이를 이용한 인슐린의 제조방법
IL118127A0 (en) 1995-05-05 1996-09-12 Lilly Co Eli Single chain insulin with high bioactivity
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
AU3247799A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1137667B1 (en) 1998-12-07 2004-11-17 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogues of glp-1
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
EP1670515A2 (en) 2003-09-19 2006-06-21 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
ES2542228T3 (es) * 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
WO2009022006A1 (en) 2007-08-15 2009-02-19 Novo Nordisk A/S Insulins with an acyl moiety comprising repeating units of alkylene glycol containing amino acids
AU2008288413B2 (en) 2007-08-15 2013-09-26 Novo Nordisk A/S Insulin analogues with an acyl and aklylene glycol moiety
US20100292133A1 (en) 2007-09-05 2010-11-18 Novo Nordisk A/S Truncated glp-1 derivaties and their therapeutical use
US20100261637A1 (en) * 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
HUE032284T2 (en) * 2008-03-18 2017-09-28 Novo Nordisk As Protease-stabilized, acylated insulin analogues
MX377589B (es) 2010-12-16 2025-03-10 Novo Nordisk As Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
US8788849B2 (en) * 2011-02-28 2014-07-22 Sandisk Technologies Inc. Method and apparatus for protecting cached streams
KR102072202B1 (ko) 2012-03-22 2020-01-31 노보 노르디스크 에이/에스 Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
HUE049152T2 (hu) * 2012-07-01 2020-09-28 Novo Nordisk As Hosszantartó hatású GLP-1 peptidek alkalmazása
RS58039B1 (sr) 2013-05-02 2019-02-28 Novo Nordisk As Oralno doziranje glp-1 jedinjenja
BR112018002416A2 (pt) * 2015-08-25 2018-09-18 Novo Nordisk As derivados de insulina e seus usos médicos
WO2017205191A1 (en) * 2016-05-24 2017-11-30 Merck Sharp & Dohme Corp. Insulin receptor partial agonists and glp-1 analogues
ES2886837T3 (es) * 2016-12-16 2021-12-21 Novo Nordisk As Composiciones farmacéuticas que contienen insulina
CN109248323B (zh) * 2017-07-14 2023-09-08 杭州先为达生物科技有限公司 酰化的glp-1衍生物
WO2019200594A1 (zh) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 酰化的glp-1衍生物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
AU2020418207A1 (en) * 2019-12-30 2022-08-25 Gan & Lee Pharmaceuticals Co., Ltd. Long-acting GLP-1 compound
BR112022013009A2 (pt) * 2019-12-30 2022-09-06 Gan & Lee Pharmaceuticals Co Ltd Derivados de insulina, composição farmacêutica, uso do derivado da insulina e métodos para tratar ou prevenir diabetes, para aumentar a capacidade de um derivado de insulina e para aumentar a potência de um derivado de insulina
US20240316157A1 (en) 2021-06-25 2024-09-26 Gan & Lee Pharmaceuticals Co., Ltd. Pharmaceutical composition of pcsk9 inhibitor and glp-1 receptor agonist
CN117561072A (zh) 2021-06-25 2024-02-13 甘李药业股份有限公司 含glp-1化合物的药物组合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Jesper LAU et al.，"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide"，Journal of Medicinal Chemistry，2015年09月11日，Vol. 58, No. 18，p.7370-7380，DOI: 10.1021/ACS.JMEDCHEM.5B00726
Jia Ying CHEANG et al.，"Glucagon‐Like Peptide‐1 (GLP‐1)‐Based Therapeutics: Current Status and Future Opportunities beyond Type 2 Diabetes"，ChemMedChem，2018年02月28日，Vol. 13, No. 7，p.662-671，DOI: 10.1002/cmdc.201700781
Lotte Bjerre KNUDSEN et al.，"The Discovery and Development of Liraglutide and Semaglutide"，Frontiers in Endocrinology，2019年04月12日，Vol. 10，p. 1-32，DOI: 10.3389/fendo.2019.00155
Tamer COSKUN et al.，"LY3298176, a novel dual GIP and GLP-1 receptoragonist for the treatment of type 2 diabetes mellitus: From discovery toclinical proof of concept"，Molecular Metabolism，2018年12月，Vol. 18，p.3-14，DOI: 10.1016/j.molmet.2018.09.009

Also Published As

Publication number Publication date
EP4086277A4 (en) 2024-02-14
MX2022008139A (es) 2022-10-03
CN119060161A (zh) 2024-12-03
CN114901680B (zh) 2024-09-27
CN119060163A (zh) 2024-12-03
WO2021136303A1 (zh) 2021-07-08
CN119529057A (zh) 2025-02-28
US20240239859A1 (en) 2024-07-18
CN114901680A (zh) 2022-08-12
US12703731B2 (en) 2026-08-11
CA3166496A1 (en) 2021-07-08
BR112022013042A2 (pt) 2022-10-18
CN119060162A (zh) 2024-12-03
AU2020418207A1 (en) 2022-08-25
US20250011385A1 (en) 2025-01-09
CN119060162B (zh) 2026-07-10
JP2023510218A (ja) 2023-03-13
KR20220119731A (ko) 2022-08-30
EP4086277A1 (en) 2022-11-09

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231225

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231225

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250924

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260526

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260624

R150 Certificate of patent or registration of utility model

Ref document number: 7885124

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150